Rehabilitation Training Can Significantly Increase the Serum IL-11 Levels and Improve the Prognosis in Ischemic Stroke Patients

Li, Xiaoliu; Zhang, Jing; Wang, Qiang; Xiang, Lian; Dong, Jing

doi:https://doi.org/10.1155/2023/1865760

Mediators of Inflammation

On this page

Abstract Introduction Methods Results Discussion Conclusion Data Availability Conflicts of Interest Authors’ Contributions References Copyright Related Articles

Special Issue

The Role of Inflammation Mediators in Neurological Diseases

View this Special Issue

Research Article | Open Access

Volume 2023 | Article ID 1865760 | https://doi.org/10.1155/2023/1865760

Rehabilitation Training Can Significantly Increase the Serum IL-11 Levels and Improve the Prognosis in Ischemic Stroke Patients

Xiaoliu Li,¹Jing Zhang,²Qiang Wang,³Lian Xiang,⁴and Jing Dong⁵

Academic Editor: Feng Zhang

Received21 Sept 2022

Revised26 Oct 2022

Accepted24 Nov 2022

Published22 Feb 2023

Abstract

We aimed to explore the expression of IL-11 in ischemic stroke patients and its correlation with rehabilitation training and prognosis. The present randomized control study recruited ischemic stroke patients who were admitted during March 2014 to November 2020. All patients underwent computer tomography (CT) and magnetic resonance imaging (MRI) examination. All patients were randomly divided into two groups, including rehabilitation training (RT) group and control group. The patients in the RT group were received rehabilitation training within 2 days after the vital signs were stable while control group received routine nursing. The serum interleukin- (IL-) 11 levels were measured by enzyme-linked immunosorbent assay (ELISA) when patients were just hospitalized and 6 h, 24 h, 48 h, 72 h, and 90 h after treatment. Demographic, clinical statistics, imaging data, and the National Institutes of Health Stroke Scores (NIHSS) were recorded. The modified Rankin Scale (mRS) scores were measured after 90 days treatment to assess the prognosis of ischemic patients. The serum IL-11 levels of the RT group elevated more quickly during the study time compared with the control group. In addition, the NIHSS and mRS scores of ischemic stroke patients in the RT group were significantly lower than that in the control group. The NIHSS score, the proportion receiving rehabilitation training, and the levels of IL-11, triglyceride (TG), and high-density leptin cholesterol (HDLC) of ischemic stroke patients in the group were remarkably elevated than that in the group. However, the serum IL-11 levels of ischemic stroke patients were obviously decreased in the group. IL-11 could be a potential diagnostic biomarker of poor prognosis of ischemic stroke patients. Furthermore, IL-11, NIHSS score, and rehabilitation training were the risk factors for poor prognosis of ischemic stroke patients. This study demonstrated that the ischemic stroke patients in the RT group had higher serum IL-11 levels and better prognosis. This study might provide a new approach to improve the prognosis of patients with ischemic stroke. This trial is registered with ChiCTR-PNR-16007706.

1. Introduction

As a major reason of permanent disability [1, 2], stroke influences 13.7 million people worldwide and causes 5.5 million deaths each year [3, 4]. Stroke is the leading cause of disability in adults, and about 90% stroke patients leave some residual defects [5]. Ischemic stroke patients account for about 85% of all stroke patients [6]. Many risk factors are associated with ischemic stroke, including smoking [7], cardiac causes [8], hypertension [9], diabetes mellitus [10], oxidative stress [11], and inflammation [12, 13]. In view of the high disability rate of ischemic stroke, improving the prognosis of patients is important for the treatment of ischemic stroke.

Posttreatment rehabilitation is the most common method to improve the prognosis of ischemic stroke patients [14, 15]. In addition, inflammation after ischemia-reperfusion injury is considered as an inevitable pathological process in postischemic brain injury [16]. Dynamic changes in the release of several proinflammatory and anti-inflammatory cytokines in the brain may influence the progression of ischemic stroke. Therefore, these inflammatory factors are considered as biomarkers of the pathogenesis and prognosis of stroke [17]. However, the importance of these biomarkers in predicting the prognosis of ischemic stroke patients still needs further investigation. Interleukin-11 (IL-11) is a soluble factor in the supernatant of plasma cell tumor-stimulating cells [18]. IL-11 has many functions in vivo, including anti-inflammatory, cardioprotective, and reducing apoptosis [19]. It has been reported that IL-11 plays a protective role in ischemia-reperfusion injury of the heart, kidney, and intestine [20, 21]. A recent mouse model restriction of cerebral ischemia-reperfusion injury found that IL-11 was declined in the cerebral ischemia model, and the upregulation of the IL-11 expression could improve the cerebral ischemia neuropathy injury and neurological function score [22]. However, there is no clinical study on IL-11 in ischemic stroke patients.

In this randomized control research, we aimed to explore the expression of IL-11 in ischemic stroke patients and its correlation with rehabilitation training and prognosis. This study might reveal the clinical significance of IL-11 in ischemic stroke patients, as well as provide novel research targets for ischemic stroke treatment.

2. Methods

2.1. Subjects

The present randomized control study recruited 404 ischemic stroke patients who were admitted during March 2014 to November 2019, and all patients underwent computer tomography (CT) and magnetic resonance imaging (MRI) examination. The criteria for inclusion were as follows: (1) the ischemic stroke was diagnosed by CT or MRI according to the Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018 [23]; (2) , first onset, and admission within 48 h; and (3) patients could complete the scale assessment. The exclusion criteria included the following: (1) hemorrhagic stroke; (2) patients who were unable to complete the examination and follow-up; (3) patients with seriously infection, severe liver, renal, malignancy, and cardiovascular dysfunctions; (4) patients with epilepsy, Parkinson’s disease, or other neuropsychiatric disorders; and (5) patients with important organ failure, such as liver and kidney. Written informed consent was obtained from all participants. This research had obtained approval from the ethic committee of the Zhoupu Hospital Affiliated to Shanghai Medical College of Health and kept compliance with the Declaration of Helsinki.

All patients were randomly divided into two groups using a computer-generated list by Rv, including rehabilitation training (RT) group and control group. Uniform formula uses SPSS software (SPSS Inc., Chicago, USA). For calculation of sample size, the formula of was used. We used the NIHSS scores 3 months after admission as the main variable and the difference of NIHSS scores between two groups at least 1 as effective. The mean NIHSS scores were about after 3 months after admission according to the clinical experience. Thus, , , , and . And the minimal sample size was 189.

2.2. Treatment and Rehabilitation Training

All patients were treated with thrombolytic therapy, antiplatelet aggregation, improving circulation, neuroprotection, scavenging free radicals, and statins according to the Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018 [23]. The patients in the RT group were received rehabilitation training within 2 days after the vital signs were stable. Rehabilitation training was as follows: sitting and lying position training; improving joint range of motion, muscle strength enhancement training, and gait training; improving the range of motion of the joint by maintaining good limb position, turning over, transfer training, and passive limb movement; cognitive ability training; and social adaptability training. Refining the selection and intensity of rehabilitation training items based on individual patients’ conditions, and implementing a continuous 14-day training program, the control group received routine nursing in hospital. If the RT group patients given up training midway or the patients in the control group spontaneously carried out rehabilitation training, they would be excluded from this study. All patients were followed up for 3 months.

2.3. Blood Sampling Measurement

The serum IL-11 and other inflammatory factors levels were measured by enzyme-linked immunosorbent assay (ELISA). Blood samples of fasting cubital venous (5 mL) were collected within 24 h after admission for all cases. Samples were centrifuged at 2000 g for 15 min, following with ELISA tested using commercially available kits (IL-11 EK0419 BOSTER, , detection range 31.2 pg/mL-2000 pg/mL, IL-6 MBS175877 MyBioSource, CRP MBS177184 MyBioSource, TNF-α MBS824943 MyBioSource). The serum cytokine levels were measured when patients were just hospitalized and 24 h, 48 h, 72 h, and 90 h after treatment.

2.4. Data Collection and Scale Scoring

Demographic and clinical statistics including age, BMI, sex, smoke condition, diastolic blood pressure (DBP), systolic blood pressure (SBP) and history of hypertension, hyperlipidemia, and diabetes were collected. Using an automatic biochemical analyzer to performed whole blood test by Hitachi 7600 of Hitachi Corporation, the total cholesterol (TC), fasting plasma glucose (FPG), triglyceride (TG), low-density leptin cholesterol (LDLC), and high-density leptin cholesterol (HDLC) levels were recorded. Imaging indexes of MRI and CT including infarct location, infarct volume, multiple or single, and vulnerable plaque were collected. The National Institutes of Health Stroke Scores (NIHSS) were recorded when the subjects were hospitalized to assess the severity of stroke. Using the modified Rankin Scale (mRS) to assess the prognosis after 90 days of treatment, indicated a bad prognosis, and indicated a good prognosis.

2.5. Statistical Analysis

Data were expressed by (range) according to distribution, which was confirmed by Kolmogorov-Smirnov analysis. Mann–Whitney test or Student’s test was used for comparison between two groups. Chi-square test was used for rates. ROC curves assess the diagnostic value of IL-11 for poor prognosis of ischemic stroke patients. Logistic regression was performed for risk factors of bad outcome of ischemic stroke. is regarded as significantly different. All data used SPSS 18.0 to statistical analyses.

3. Results

3.1. Clinical Characteristics of All Participants

This study enrolled 404 ischemic stroke patients. All patients were randomly divided into the RT group () and control group (). The basic characteristics of two group patients were shown in Table 1. About 70% of ischemic stroke patients had hypertension, 30% had hyperlipidemia, and about 45% had hyperglycemia. There was no significant difference between the two groups in terms of basic clinical information and expression of serum cytokine markers at the time of admission.

3.2. Serum IL-11 Expression and Clinical Data in Each Group during the Study Time

Then, we draw line graphs of all subjects to show the dynamic variations of the IL-11 expression. It was observed that the IL-11 levels were increased gradually with treatment in both groups (Figure 1). We found no obvious differences of the IL-11 expression between two groups when the patients were just hospitalized. However, the serum IL-11 levels of the RT group elevated more quickly during the study time (), while IL-6 and TNF-α decreased quickly in the RT group. To further investigate the correlation between the recovery of ischemic stroke patients and rehabilitation training, we measured NIHSS and mRS scores after 90 days treatment. The results indicated that the NIHSS and mRS scores of ischemic stroke patients in the RT group were significantly lower than that in the control group (Figure 2, ). Spearman’s analysis showed that IL-11 was negatively correlated with NIHSS and mRS scores (Table 2).

3.3. Connection of Serum IL-11 Levels, Clinical Data, and Prognosis of Ischemic Stroke Patients

All patients measured mRS scores after 90 days of treatment and divided into two groups including the group and group. Compared with the demographic and clinical data of two groups when the patients were hospitalized, we found no significant differences in age, sex, BMI, smoking proportion and levels of FPG, TC, and LDLC between the group and group (Table 3). The NIHSS score, infarct volume, and the levels of IL-6, TG, and HDLC of ischemic stroke patients in the group were remarkably elevated than the ischemic stroke patients in the group (). In addition, the serum IL-11 levels of ischemic stroke patients were obviously decreased in the group.

3.4. Diagnostic Value of IL-11 for Poor Prognosis of Ischemic Stroke Patients

We draw ROC curves to assess the diagnostic value of IL-11 for poor prognosis of ischemic stroke patients. The result showed that IL-11 could be a potential diagnostic biomarker of poor prognosis of ischemic stroke patients (Figure 3), the AUC of IL-11 was 0.965, cutoff value was 87.31 pg/mL, sensitivity was 87.5%, and specificity was 87.2%.

3.5. Risk Factors of Poor Prognosis of Ischemic Stroke Patients by Logistic Regression Analysis

Finally, the risk variables for poor prognosis in ischemic stroke patients were calculated using binary regression analysis. It was found that IL-11 (95% CI 0.346~0.799, ), NIHSS score, infarct volume, TG, HDLC, and IL-6 were the risk factors for bad prognosis of ischemic stroke patients (Table 4).

4. Discussion

Although intravenous thrombolysis and thrombectomy can be effective in the treatment of ischemic stroke, progressive neuronal degeneration and functional loss remain difficult to resolve during treatment and rehabilitation. Cerebral ischemia promotes the production of proinflammatory mediators and induces cell death and cell dysfunction, thus inducing neuroinflammation. Excessive inflammation can produce neurotoxins and brain edema. Recently, poststroke immune response has recently a new breakthrough goal in the treatment strategy of ischemic stroke [24, 25]. In our present research, we found that the serum levels of IL-11 were declined in ischemic stroke patients with bad prognosis.

Rehabilitation training can improve the prognosis and daily living of ischemic stroke patients. A nationwide retrospective cohort study in Japan confirmed that early rehabilitation training can improve the daily living of ischemic stroke patients [26]. The relationship between rehabilitation training and changes of inflammatory factors has been controversial. Previous study found that the rehabilitation after ischemic stroke depended on the start time of exercise, and premature exercise after stroke leads to increased expression of proinflammatory factors [27]. Another research showed that rehabilitation training could not reduce the expression of inflammation [28]. In our research, the results indicated that the serum IL-11 levels of the RT group elevated more quickly during the study time.

Some biomarkers have been found correlated to the prognosis of ischemic stroke patients. Kwan et al. found that the increasing of IL-6 was related to the severity and infection of ischemic stroke patients, and serum IL-6 levels could predict the mortality in the first two years after stroke [29]. Wang et al. supported that high macrophage migration inhibitory factor levels were independently related to the severity of ischemic stroke patients, as well as the bad prognosis [30]. Li’s study showed that the serum IL-4, IL-5, IL-7, and IL-9 levels decreased in the ischemic stroke patients with poor outcome [30]. Wang et al. confirmed that the plasma high mobility group box protein 1 has a satisfactory predictive value for cerebral ischemia-reperfusion injury in ischemic stroke patients [31]. IL-11 is a multifunctional cytokine which is involved in the development of various diseases [21, 32]. Yang and Shao’s study showed that the serum IL-11 levels were correlated with the severity of hypertensive intracerebral hemorrhage patients [33]. Ren et al. found that IL-11 was a biomarker in diagnosis of pancreatic cancer, and it might be used to predict the prognosis of pancreatic cancer patients [34]. Zhang et al. [22] and Obana et al.’s [35] animal studies confirmed that IL-11 played a protective role in ischemia-reperfusion injury. In the present study, we also demonstrated for the first time in a clinical trial that IL-11 was progressively elevated in recovering of ischemic stroke patients and correlated with cytokines and prognosis of ischemic stroke patients.

4.1. Limitations

This present research also has some limitations. First, this is a single-center study. Secondly, we only checked a small number of biomarkers. Thirdly, the molecular mechanism of IL-11 affecting ischemic stroke development is unclear.

5. Conclusion

In summary, the present study showed that the ischemic stroke patients in the RT group had higher serum IL-11 levels and better prognosis, indicating that rehabilitation training might improve the prognosis of ischemic stroke patients and elevate the levels of IL-11. This study may provide a new approach to screen ischemic stroke patients with worse prognosis in advance, as well as provide a new approach to improve the prognosis of ischemic stroke patients.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding authors on reasonable request.

Conflicts of Interest

The authors declared no conflict of interest.

Authors’ Contributions

Xiaoliu Li, Jing Zhang, and Qiang Wang contributed equally to this work.

References

S. T. Hou and J. P. MacManus, “Molecular mechanisms of cerebral ischemia-induced neuronal death,” International Review of Cytology, vol. 221, pp. 93–148, 2002.
View at: Publisher Site | Google Scholar
R. L. Sacco, S. E. Kasner, J. P. Broderick et al., “An updated definition of stroke for the 21st century,” Stroke, vol. 44, no. 7, pp. 2064–2089, 2013.
View at: Publisher Site | Google Scholar
“Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016,” Lancet Neurology, vol. 18, no. 5, pp. 459–480, 2019.
View at: Publisher Site | Google Scholar
V. L. Feigin, M. Brainin, B. Norrving et al., “World Stroke Organization (WSO): global stroke fact sheet 2022,” International Journal of Stroke, vol. 17, no. 1, pp. 18–29, 2022.
View at: Publisher Site | Google Scholar
J. L. Hinkle and M. M. Guanci, “Acute ischemic stroke review,” Journal of Neuroscience Nursing, vol. 39, no. 5, pp. 285–293,310, 2007.
View at: Publisher Site | Google Scholar
N. Li, X. Wang, C. Sun et al., “Change of intestinal microbiota in cerebral ischemic stroke patients,” BMC Microbiology, vol. 19, no. 1, p. 191, 2019.
View at: Publisher Site | Google Scholar
E. Boot, M. S. Ekker, J. Putaala, S. Kittner, F. E. De Leeuw, and A. M. Tuladhar, “Ischaemic stroke in young adults: a global perspective,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 91, no. 4, pp. 411–417, 2020.
View at: Publisher Site | Google Scholar
P. Soros and V. Hachinski, “Cardiovascular and neurological causes of sudden death after ischaemic stroke,” The Lancet Neurology, vol. 11, no. 2, pp. 179–188, 2012.
View at: Publisher Site | Google Scholar
T. H. Kim, P. S. Yang, H. T. Yu et al., “Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population,” European Heart Journal, vol. 40, no. 10, pp. 809–819, 2019.
View at: Publisher Site | Google Scholar
J. B. Echouffo-Tcheugui, H. Xu, R. A. Matsouaka et al., “Diabetes and long-term outcomes of ischaemic stroke: findings from get with the guidelines-stroke,” European Heart Journal, vol. 39, no. 25, pp. 2376–2386, 2018.
View at: Publisher Site | Google Scholar
C. L. Allen and U. Bayraktutan, “Oxidative stress and its role in the pathogenesis of ischaemic stroke,” International Journal of Stroke, vol. 4, no. 6, pp. 461–470, 2009.
View at: Publisher Site | Google Scholar
N. R. Sims and H. Muyderman, “Mitochondria, oxidative metabolism and cell death in stroke,” Biochimica et Biophysica Acta, vol. 1802, no. 1, pp. 80–91, 2010.
View at: Publisher Site | Google Scholar
B. Campbell, D. A. De Silva, M. R. Macleod et al., “Ischaemic stroke,” Nature Reviews Disease Primers, vol. 5, no. 1, p. 70, 2019.
View at: Publisher Site | Google Scholar
K. Sandberg, M. Kleist, L. Falk, and P. Enthoven, “Effects of twice-weekly intense aerobic exercise in early subacute stroke: a randomized controlled trial,” Archives of Physical Medicine and Rehabilitation, vol. 97, no. 8, pp. 1244–1253, 2016.
View at: Publisher Site | Google Scholar
Q. Wang, M. Wills, F. Li, X. Geng, and Y. Ding, “Remote ischemic conditioning with exercise (RICE) promotes functional rehabilitation following ischemic stroke,” Neurological Research, vol. 43, no. 11, pp. 874–883, 2021.
View at: Publisher Site | Google Scholar
X. Li, S. Lin, X. Chen et al., “The prognostic value of serum cytokines in patients with acute ischemic stroke,” Aging and Disease, vol. 10, no. 3, pp. 544–556, 2019.
View at: Publisher Site | Google Scholar
S. J. Donkel, B. Benaddi, D. Dippel, C. H. Ten, and M. de Maat, “Prognostic hemostasis biomarkers in acute ischemic stroke,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 39, no. 3, pp. 360–372, 2019.
View at: Publisher Site | Google Scholar
M. Negahdaripour, N. Nezafat, and Y. Ghasemi, “A panoramic review and in silico analysis of IL-11 structure and function,” Cytokine & Growth Factor Reviews, vol. 32, pp. 41–61, 2016.
View at: Publisher Site | Google Scholar
B. Corden, E. Adami, M. Sweeney, S. Schafer, and S. A. Cook, “IL‐11 in cardiac and renal fibrosis: late to the party but a central player,” British Journal of Pharmacology, vol. 177, no. 8, pp. 1695–1708, 2020.
View at: Publisher Site | Google Scholar
M. Sabzevary-Ghahfarokhi, M. Shohan, H. Shirzad et al., “The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis,” BMC Immunology, vol. 19, no. 1, p. 17, 2018.
View at: Publisher Site | Google Scholar
J. Ye, Z. Wang, D. Ye et al., “Increased Interleukin-11 levels are correlated with cardiac events in patients with chronic heart failure,” Mediators of Inflammation, vol. 2019, Article ID 1575410, 8 pages, 2019.
View at: Publisher Site | Google Scholar
B. Zhang, H. X. Zhang, S. T. Shi et al., “Interleukin-11 treatment protected against cerebral ischemia/reperfusion injury,” Biomedicine & Pharmacotherapy, vol. 115, article 108816, 2019.
View at: Publisher Site | Google Scholar
D. Zhong and W. U. Bo, “Interpretation of "Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018",” Chinese Journal of Contemporary Neurology & Neurosurgery, vol. 19, no. 11, p. 897, 2019.
View at: Google Scholar
S. Xu, J. Lu, A. Shao, J. H. Zhang, and J. Zhang, “Glial cells: role of the immune response in ischemic stroke,” Frontiers in Immunology, vol. 11, p. 294, 2020.
View at: Publisher Site | Google Scholar
S. Shaafi, E. Sharifipour, R. Rahmanifar et al., “Interleukin-6, a reliable prognostic factor for ischemic stroke,” Iranian Journal of Neurology, vol. 13, no. 2, pp. 70–76, 2014.
View at: Google Scholar
M. Yagi, H. Yasunaga, H. Matsui et al., “Impact of rehabilitation on outcomes in patients with ischemic stroke: a nationwide retrospective cohort study in Japan,” Stroke, vol. 48, no. 3, pp. 740–746, 2017.
View at: Publisher Site | Google Scholar
F. Li, J. J. Pendy, J. N. Ding et al., “Exercise rehabilitation immediately following ischemic stroke exacerbates inflammatory injury,” Neurological Research, vol. 39, no. 6, pp. 530–537, 2017.
View at: Publisher Site | Google Scholar
I. Vogiatzis, G. Stratakos, D. C. Simoes et al., “Effects of rehabilitative exercise on peripheral muscle TNFα, IL-6, IGF-I and MyoD expression in patients with COPD,” Thorax, vol. 62, no. 11, pp. 950–956, 2007.
View at: Publisher Site | Google Scholar
J. Kwan, G. Horsfield, T. Bryant et al., “IL-6 is a predictive biomarker for stroke associated infection and future mortality in the elderly after an ischemic stroke,” Experimental Gerontology, vol. 48, no. 9, pp. 960–965, 2013.
View at: Publisher Site | Google Scholar
C. W. Wang, P. J. Ma, Y. Y. Wang et al., “Serum level of macrophage migration inhibitory factor predicts severity and prognosis in patients with ischemic stroke,” Cytokine, vol. 115, pp. 8–12, 2019.
View at: Publisher Site | Google Scholar
J. Wang, Y. Jiang, D. Zeng, W. Zhou, and X. Hong, “Prognostic value of plasma HMGB1 in ischemic stroke patients with cerebral ischemia-reperfusion injury after intravenous thrombolysis,” Journal of Stroke and Cerebrovascular Diseases, vol. 29, no. 9, article 105055, 2020.
View at: Publisher Site | Google Scholar
T. L. Putoczki and M. Ernst, “IL-11 signaling as a therapeutic target for cancer,” Immunotherapy, vol. 7, no. 4, pp. 441–453, 2015.
View at: Publisher Site | Google Scholar
G. Yang and G. F. Shao, “Elevated serum IL-11, TNF α, and VEGF expressions contribute to the pathophysiology of hypertensive intracerebral hemorrhage (HICH),” Neurological Sciences, vol. 37, no. 8, pp. 1253–1259, 2016.
View at: Publisher Site | Google Scholar
C. Ren, Y. Chen, C. Han, D. Fu, and H. Chen, “Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer,” Tumour Biology, vol. 35, no. 11, pp. 11467–11472, 2014.
View at: Publisher Site | Google Scholar
M. Obana, K. Miyamoto, S. Murasawa et al., “Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 303, no. 5, pp. H569–H577, 2012.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Xiaoliu Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

389

Downloads

423

Citations